1. Popat S, Felip E, Dafni U, Pope A, Stahel RA, et al., for the ETOP 13–18 BEAT-meso Collaborators: BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13–18 trial. Journal of Clinical Oncology 2024; 42 (17): 2024 ASCO Annual Meeting II LBA8002; DOI: 10.1200/JCO.2024.42.17_suppl.LBA8002.
2. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, et al.: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 30 January 2021; 397 (10272): 375–86; DOI: 10.1016/S0140–6736(20)32714–8. Epub 31 January 2021. Erratum in: Lancet 20 February 2021; 397 (10275): 670; DOI: 10.1016/S0140–6736(21)00369-X.
3. Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al.: Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 16 December 2023; 402 (10419): 2295–306; DOI: 10.1016/S0140–6736(23)01613–6.
4. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, et al., French Cooperative Thoracic Intergroup (IFCT): Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2 April 2016; 387 (10026): 1405–14; DOI: 10.1016/S0140–6736(15)01238–6. Epub 31 December 2015. Erratum in: Lancet 2 April 2016; 387 (10026): e24; DOI: 10.1016/S0140–6736(16)30084–8.
5. Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H: The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol 11 November 2019; 37 (1): 2; DOI: 10.1007/s12032–019–1329–2.